Josh Gottheimer's ABBV trades
- The latest ABBV trade was a sale on May 5, 2026, when ABBV closed at $206.11. It closed at $286.85 on Nov 3, 2026 (+39%).
- All 3 ABBV purchases we can price are higher today. The median one is +42%, against +35% for the S&P 500 over the same holding periods.
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Josh Gottheimer reported 5 ABBV transactions in 3 filings with the House Clerk for 2025–2026: 3 purchases and 2 sales of AbbVie Inc., with trade dates from Apr 1, 2025 to May 5, 2026. The median gap between trade date and filing date is 29 days, and every trade was reported within 45 days.
- 5
- 3 / 2
- $5K – $75K
- 2026-06-03
ABBV transactions reported by Josh Gottheimer
| Type | Owner | ||||
|---|---|---|---|---|---|
AbbVie Inc. Common Stock ABBV | Sale | Joint | $1,001 - $15,000 | 2026-06-03 #20034693 | |
AbbVie Inc. Common Stock ABBV | Purchase | Joint | $1,001 - $15,000 | 2025-06-11 #20030462 | |
AbbVie Inc. Common Stock ABBV | Sale | Joint | $1,001 - $15,000 | 2025-05-14 #20030338 | |
AbbVie Inc. Common Stock ABBV | Purchase | Joint | $1,001 - $15,000 | 2025-05-14 #20030338 | |
AbbVie Inc. Common Stock ABBV | Purchase | Joint | $1,001 - $15,000 | 2025-05-14 #20030338 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 5 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 3
- 31–45 days
- 2
- Over 45 days
- 0
- Median / longest
- 29d / 43d
What Josh Gottheimer's ABBV filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- AbbVie Inc. financials and filings
Audited SEC figures, what moves ABBV, and primary sources.
Compare ABBV vs LLY side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchOther members of Congress who reported ABBV
More tickers reported by Josh Gottheimer
Josh Gottheimer and ABBV: questions
Did Josh Gottheimer buy or sell ABBV?
House Clerk filings for 2025 and 2026 show 3 purchases and 2 sales of AbbVie Inc. (ABBV) reported by Josh Gottheimer, between 2025-04-01 and 2026-05-05. Reported owner: Joint.
How much ABBV did Josh Gottheimer trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $5K – $75K across 5 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last ABBV filing by Josh Gottheimer?
The most recent filing that includes a ABBV trade was filed on 2026-06-03. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with AbbVie Inc.. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Josh Gottheimer ABBV disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included